Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EBITDA (2023 - 2025)

Rallybio's EBITDA history spans 3 years, with the latest figure at $16.0 million for Q3 2025.

  • For Q3 2025, EBITDA rose 242.73% year-over-year to $16.0 million; the TTM value through Sep 2025 reached -$14.3 million, up 78.5%, while the annual FY2024 figure was -$57.7 million, 22.35% up from the prior year.
  • EBITDA for Q3 2025 was $16.0 million at Rallybio, up from -$9.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $16.0 million in Q3 2025 and bottomed at -$20.0 million in Q4 2023.
  • The 3-year median for EBITDA is -$16.2 million (2024), against an average of -$12.3 million.
  • The largest annual shift saw EBITDA decreased 11.36% in 2024 before it skyrocketed 242.73% in 2025.
  • A 3-year view of EBITDA shows it stood at -$20.0 million in 2023, then soared by 44.33% to -$11.1 million in 2024, then soared by 243.77% to $16.0 million in 2025.
  • Per Business Quant, the three most recent readings for RLYB's EBITDA are $16.0 million (Q3 2025), -$9.7 million (Q2 2025), and -$9.5 million (Q1 2025).